Featured Studies

Researchers at the National Institutes of Health (NIH) are testing NX-2127, an oral drug that degrades a protein in cancer cells called Bruton's tyrosine kinase (BTK), instead of inhibiting or blocking it like other drugs. NX-2127 may also stimulate your immune T-cells to attack the cancer.

The National Institute of Neurological Disorders and Stroke at the National Institutes of Health Clinical Center is looking for individuals with severe epilepsy or individuals who have experienced persistent seizure activity that cannot be controlled with medication, to participate in this research study. The goal of this research study is to provide surgical treatment to control these types of seizures. Participation requires an inpatient stay of up to 4 weeks, plus 3 outpatient visits within 2 years after surgery.

Heart disease is the leading cause of death and disability in the United States. Omega-7 fatty acids are found in the oil extracted from certain fish and nuts like macadamia. Palmitoleic acid is one of the most common omega-7 fatty acids. Many studies suggest that this oil is good for heart health. Researchers at the National Institutes of Health (NIH) want to find out more about these potential benefits.

Researchers at NIH are testing a new therapy in patients diagnosed with colitis due to chronic granulomatous disease (CGD). The research aims to see if restoring the gut microbiome reduces inflammation in the colon.

Research Study 000444-H investigating how well the following vaccines work in patients with CLL/SLL malignancies: SHINGRIX and influenza vaccine. If you are currently receiving treatment for your CLL/SLL (e.g. ibrutinib, acalabrutinib or venetoclax), you may be able to participate.

The National Institutes of Health (NIH) is conducting a research study of the causes and responses to treating multiple sclerosis (MS) and other brain and spine inflammatory conditions. Join this study if you have MS or a related disease. Although the study does not offer treatment options, your participation may help in future discoveries and inspire hope.

Researchers want to see if they can measure the amount of anti-cancer drug, Abemaciclib in a brain tumor and brain fluid after a patient has taken this drug for a few days. These findings can help explain how much drug gets into the brain and how drugs work to shrink high grade gliomas to improve outcomes for these patients.